Draft Guidance Issued for Influenza Drug Development

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration has released a draft guidance for industry entitled Influenza: Developing Drugs for Treatment and/or Prophylaxis.

Rockville, MD (Feb. 19)-The US Food and Drug Administration released a draft guidance for industry titled Influenza: Developing Drugs for Treatment and/or Prophylaxis. This document aims to assist companies in all phases of influenza drug development by addressing common questions the agency often receives regarding the potential for the emergency use of influenza drugs. FDA developed the draft in response to recent concerns regarding pandemic influenza and the ongoing public health risks of seasonal influenza.

The document covers preclinical development, early-phase clinical development, and Phase III protocol designs and endpoints specific to influenza A and influenza B drugs. The draft also discusses the role of animal studies as part of drug development, emphasizing that cell culture and animal-model studies can make valuable contributions to clinical-trial design. The document also describes considerations relating to the potential for emergency use of influenza drugs.

FDA will receive comments about the draft until May 21, 2009.

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content